LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: Springer Verlag
Languages: English
Types: Article
Subjects:
The National Institute for Health and Care Excellence (NICE) invited Boehringer Ingelheim GmbH, the manufacturer of alteplase, to submit evidence for the clinical and cost-effectiveness of alteplase for the prevention of strokes within a 0–4.5 h window. The comparator was standard medical and supportive management that does not include alteplase. This paper provides a description of the company submission, the Evidence Review Group (ERG) review and NICE's subsequent decisions. Clinical effectiveness evidence for alteplase was derived from 5 trials. For the 3–4.5 h treatment window, alteplase did not show a statistically significant treatment effect on death or dependency at three months follow-up. For the 0–4.5 h treatment window data from a meta-analysis of 3 trials indicated that the reduction of death and dependency was statistically significant. In both cases there was a significant increase in symptomatic intracranial haemorrhage. The economic model described in the manufacturer's submission was considered by the ERG to meet the NICE reference case. The model structure was considered to be appropriate and the ERG has no major concerns regarding the selection of data used within the model. The incremental cost-effectiveness ratios (ICER) for all treatment windows were well below accepted willingness to pay thresholds. The ERG had no major concerns regarding the completeness of the submission or the robustness of the evidence presented. For all treatment windows considered, alteplase was found to be cost-effective compared with standard treatment.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Deaths Registered in England and Wales in 2010, by Cause. Statistical Bulletin.Office for National Statistics, 2011.http://www.ons.gov.uk/ons/rel/vsob1/mortality-statistics-- deaths-registered-in-england-and-wales--series-dr-/2010/stb-deaths-by-cause2010.html. Accessed October 2012 Mant, J., Wade, D.T., Winner, S. Health care needs assessment: stroke Health care needs assessment: the epidemiologically based needs assessment review. Oxford: Radcliffe Medical Press 2004:141-244 Department of Health. Reducing Brain Damage: Faster access to better stroke care, National Audit Office Report 2005 Giles, M.F., Rothwell, P.M. Substantial underestimation of the need for outpatient services for TIA and minor stroke. Age Ageing 2007;36:676-680.
    • Adamson, J., Beswick, A., Ebrahim, S., Is stroke the most common cause of disability? J Stroke and Cerbrovasc Dis 2004;13:171-177.
    • The Joint Formulary Committee. British National Formulary, edition 63. 2012. BMJ Group and Pharmaceutical Press. 2012.
    • Wardlaw, J.M., Murray, V., Berge, E., Del Zoppo, G.J. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009;doi:10.1002/14651858.CD000213.pub2.
    • Sandercock, P., Berge, E., Dennis, M., Forbes, J., Hand, P., Kwan, J. et al. A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS. Health Technol Assess2002;6(26):1-112.
    • Lees, K.R., Bluhmki, E., von, K.R., Brott, T.G., Toni, D., Grotta, J.C. et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695- 1703.
    • Youman, P., Wilson, K., Harraf, F., Kalra, L. (2003). The Economic Burden of Stroke in the United Kingdom. Pharmacoeconomics 2003;21:43-50.
    • PSSRU (Personal Social Services Research Unit) (2011). Unit costs of Health and Social Care 2011.
    • http://www.pssru.ac.uk/pdf/uc/uc2011/uc2011.pdf Accessed October 12th 2014.
    • Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. The Lancet 2007;369:275-282.
    • National Institute for Health and Technology Appraisal (NICE). Guide to the methods of technology appraisal. 2008. London.
    • https://www.nice.org.uk/proxy/?sourceUrl=http%3a%2f%2fwww.nice.org.uk%2fmedia %2fB52%2fA7%2fTAMethodsGuideUpdatedJune2008.pdf Accessed 18th August 2014
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article